Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 1/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.46 |
| ▸ | WNT3A | P56704 | 4/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KLK3 | P07288 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | WNT1 | P04628 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5823589 | 0.90 | CRBN (0.54) | FASNCRBNNAMPTALDH1A1KMT2A | |
| SCHEMBL13216394 | 0.81 | HPGD (0.61) | FASNCTNNB1WNT3AALDH1A1HPGD | |
| SCHEMBL5823576 | 0.79 | HPGD (0.65) | ALDH1A1KMT2AHPGDGRIA3GRIA4 | |
| SCHEMBL5756447 | 0.77 | GRIA3 (0.66) | NAMPTALDH1A1KMT2AHPGDGRIA3 | |
| SCHEMBL14176980 | 0.74 | HSD11B1 (0.47) | HPGDAKR1C3HRH3PLA2G7 | |
| SCHEMBL13486223 | 0.72 | KDM4E (0.59) | CTNNB1WNT3AALDH1A1KMT2AMEN1 | |
| SCHEMBL7559546 | 0.72 | CA12 (0.56) | GRIA3GRIA4MAPT | |
| SCHEMBL25416254 | 0.71 | HPGD (0.58) | FASNCRBNALDH1A1KMT2AHPGD | |
| SCHEMBL27775524 | 0.71 | CTNNB1 (0.57) | FASNCTNNB1WNT3ANAMPTALDH1A1 | |
| SCHEMBL703854 | 0.71 | CTNNB1 (0.65) | FASNCTNNB1WNT3ANAMPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060063707-A1 | Compositions for enhancing memory and methods therefor | LIFELIKE BIOMATIC, INC. (US) | 2006-03-23 | — | — | US | claimed |
| US-20170209425-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | UNIV CASE WESTERN RESERVE (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170209425-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | UNIV CASE WESTERN RESERVE (US) | 2017-07-27 | — | — | US | disclosed |
| EP-0883403-B1 | METHOD FOR TREATING SEXUAL DYSFUNCTIONS | UNIV CALIFORNIA (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20100035877-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR NIH | 2010-02-11 | — | — | US | disclosed |
| US-20100035877-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR NIH | 2010-02-11 | — | — | US | disclosed |
| US-20080176793-A1 | UPREGULATING ACTIVITY OR EXPRESSION OF BDNF TO MITIGATE COGNITIVE IMPAIRMENT IN ASYMPTOMATIC HUNTINGTON'S SUBJECTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080139472-A1 | UPREGULATING BDNF LEVELS TO MITIGATE MENTAL RETARDATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-06-12 | — | — | US | disclosed |
| US-20060063707-A1 | Compositions for enhancing memory and methods therefor | LIFELIKE BIOMATIC, INC. (US) | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063707-A1 | Compositions for enhancing memory and methods therefor | GRIN1, GRIN3A, GRIN2A | FASN 3748/4885CTNNB1 3859/4885WNT3A 3033/4885 |
| US-20080176793-A1 | UPREGULATING ACTIVITY OR EXPRESSION OF BDNF TO MITIGATE COGNITIVE IMPAIRMENT IN ASYMPTOMATIC HUNTINGTON'S SUBJECTS | BDNF, HTT, NTRK2 | FASN 1075/4885CTNNB1 4099/4885WNT3A 2701/4885 |
| US-20170209425-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | NTRK2, BDNF, NGF | FASN 3187/4885CTNNB1 4086/4885WNT3A 1462/4885 |
| US-20080139472-A1 | UPREGULATING BDNF LEVELS TO MITIGATE MENTAL RETARDATION | BDNF, MECP2, NTRK2 | FASN 4074/4885CTNNB1 4489/4885WNT3A 3582/4885 |
| US-20100035877-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | NTRK2, NGF, BDNF | FASN 3542/4885CTNNB1 2998/4885WNT3A 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.